CA-MARY-KAY
6.11.2020 15:09:07 CET | Business Wire | Press release
Glamhive announced its third online conference to be held on November 14. The Glamhive Digital Fall Style and Beauty Summit will bring together top fashion and beauty leaders, from Sarah Jessica Parker's stylist to Kim Kardashian's hairstylist. The innovative leaders will discuss all things fashion, wellness, beauty, and more. Stephanie Sprangers and Jennifer Rade will co-host the event.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201106005072/en/
"I'm excited to co-host the Glamhive LIVE Fall Style and Beauty summit with Stephanie. We're bringing together the most amazing stylists, makeup artists, hairstylists, designers, & entrepreneurs in the world to share everything we've learned—from how we got started to all our tips and tricks on how to have great personal style," said Jennifer Rade, celebrity stylist and costume designer. Jennifer is one of the busiest stylists working today. Her clientele has ranged from A-List stars Angelina Jolie, Abbie Cornish, Cher, and Jenna Fischer, to musicians Lady A, Pink, Marilyn Manson, Dave Matthews, Amy Winehouse, Motley Crue, and Tina Turner. Her work has been featured in many publications, including W, Vanity Fair, Marie Claire, GQ, Esquire, and Harper's Bazaar.
"Glamhive's vision is to make personal styling available to everyone, everywhere, and our digital events are a wonderful extension of that. This year has enabled us to bring our events to everyone, everywhere so that people who are fashion and beauty enthusiasts or work in the industry can learn from the best in the business," said Stephanie Sprangers, Glamhive founder. Sprangers is the Founder and Chief Executive Officer of Glamhive, the online personal styling service that brings expert personal stylists and makeup artists—recruited directly from Hollywood and Instagram—to everyone. Glamhive has developed proprietary software that allows stylists to take clients through a styling experience that is 100% online, allowing people to work with stylists anywhere in the world.
The all-day, ticketed event will feature 22 segments with 50-plus speakers. Below is an overview of some of the topics that will be covered by their all-star speaker line-up.
TOPICS:
- Zoom Style: Having Great (and Comfortable) Style
- The Making of a Fashion Stylist
- Foundations First
- How Your Home Environment Impacts Your Mood and Reflects Your Style
- How to Build the Wardrobe of Your Dreams
- 360 Style -- The Interplay of Hair, Makeup, and Wardrobe
- Entrepreneurship -- The Courage to Go For Your Dreams
- Future of the Red Carpet
- French Girl Chic and Our Obsession with Emily in Paris
- Shape Matters -- Love Yourself and Your Shape
- Style Your Health - Boosting Your Energy and Immunity
- Skincare Basics: Coaching Clients on Self-Care
- Iconic Style + How to Make a Statement with Your Style
SPEAKERS:
Speakers include celebrity stylists, makeup artists, image-makers who work with the biggest names in Hollywood and beyond, including:
Angelina Jolie, Mandy Moore, Sarah Jessica Parker, Kristen Bell, Khloe Kardashian, Robert Downey Jr, Keanu Reeves, Dwayne Johnson, Donald Glover, Sharon Stone, Serena Williams, Miranda Lambert, Julianne Moore, Liv Tyler, and more.
CELEBRITY STYLISTS:
Jennifer Rade, Ilaria Urbinati, Erin Walsh, Nicole Chavez, Jeanne Yang, Janelle Miller, Lindsey Dupuis, Tiffany Gifford, Sonia Young, Rachel Wirkus, Kesha McCloud
CELEBRITY MAKEUP ARTISTS + HAIRSTYLISTS:
Danesa Myricks, Andrew Fitzsimons, Daniel Martin, Colleen, Runne, Quinn Murphy, Sheridan Ward, Simedar Jackson, and Mia Santiago
ENTREPRENEURS, DESIGNERS, AND BUSINESS LEADERS
Cindy Eckhert (The Pink Ceiling Fund), Jonathan Sposato (Founder, PicMonkey), Carrie Colbert (Curated Capital), Summer Holl (President, Elyse Walker), Christian Juul Nielsen (Herve Leger | Aknvas), Lucy Aylen (Never Fully Dressed), Dr. Shrereene Idress, Dr. Avanti Kumar Singh
MODERATORS:
Brian Underwood (O the Oprah Magazine), Brooke Jaffe (former Fashion Director, Bloomingdales), Jack Eustace, Nicole Young (E! News), Kibwe Chase Marshall, Co-Founder, The Kelly Initiative), Jezlan Moyet.
Tickets to the conference are $99 for an all-day ticket and include a custom playlist by She-J Nikki Pennie. The presenting sponsor for the Glamhive Digital Fall Style and Beauty Summit is Mary Kay and its Mary Kay Global Design Studio. Other sponsors include NuBra USA, LEO, AKNVAS, NYDJ and more.
For more information, visit www.glamhive.com/upcoming .
About Glamhive
Glamhive was founded by entrepreneur Stephanie Sprangers in 2017 with the vision to democratize personal styling and the premise that the confidence that comes with glamour should not be exclusive to the rich and famous.
The online styling experience offers anyone with a WiFi connection access to stylists who will provide them with the support they need to be the best version of themselves. For stylists, it is a seamless end-to-end platform to help them grow their network and their business, 100% virtually.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 56 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201106005072/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom